We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FTC: Nothing Improper Done in Investigation of Watson
FTC: Nothing Improper Done in Investigation of Watson
July 30, 2010
The FTC says it did not engage in improper behavior as part of its pay-for-delay investigation into Watson Pharmaceuticals and has reaffirmed its request to subpoena CEO Paul Bisaro to see if the company brokered an illicit deal to keep Provigil generics off the market.